[Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
OBJECTIVE
This retrospective study was performed to clarify the efficacy and safety of FOLFOX regimen in aged patients with nonresectable colorectal cancer.


METHODS
We had 92 patients with nonresectable colorectal cancer between December 2005 and March 2008. The rate of introducing modified FOLFOX6 (mFOLFOX6) regimen was compared among the patients aged 75 years or older (n = 22, aged group) and those aged 74 years or younger (n = 55, younger group). In addition, relative dose intensity (RDI), therapeutic efficacy, and adverse events in the patients who were given the regimen, we compared between the groups.


RESULTS
The rate of introducing the regimen was significantly lower in the aged group (36%, n = 8) than in the younger group (79%, n = 55) (p<0.01). The RDI tended to be lower in the aged group (68.0% versus 79.9%, p=0.10). There were no significant differences in the response rate, disease-control rate, progression-free survival, and overall survival between the groups. The rate of adverse events ( > or = grade 3) was not different between the groups ( 50% versus 51%).


CONCLUSIONS
Similar to younger patients the mFOLFOX6 regimen is feasible, safe and effective in the selected aged patients, although the dose reduction may be needed for such patients.
Ishiguro
Toru
T
Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
Ishibashi
Keiichiro
K
Okada
Norimichi
N
Kuwabara
Kouki
K
Miyazaki
Tatsuya
T
Yokoyama
Masaru
M
Matsuki
Moriyuki
M
Sano
Motohiko
M
Inoue
Naohiko
N
Ishida
Hideyuki
H
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate
D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil